O	O	O	0	10	Xenogeneic	Xenogeneic	B-NP	JJ	O	3	NMOD	O
O	O	O	11	16	human	human	I-NP	JJ	O	3	NMOD	O
O	O	O	17	22	serum	serum	I-NP	NN	O	4	SUB	O
O	O	O	23	31	promotes	promote	B-VP	VBZ	O	0	ROOT	O
O	O	O	32	41	leukocyte	leukocyte	B-NP	NN	O	6	NMOD	O
O	O	O	42	50	adhesion	adhesion	I-NP	NN	O	4	OBJ	O
O	O	O	51	53	to	to	B-PP	TO	O	6	NMOD	O
O	O	O	54	61	porcine	porcine	B-NP	JJ	O	9	NMOD	O
O	O	O	62	73	endothelium	endothelium	I-NP	NN	O	7	PMOD	O
O	O	O	74	79	under	under	B-PP	IN	O	4	VMOD	O
O	O	O	80	84	flow	flow	B-NP	NN	O	12	NMOD	O
O	O	O	85	95	conditions	condition	I-NP	NNS	O	10	PMOD	O
O	O	O	95	96	,	,	O	,	O	4	P	O
O	O	O	97	105	possibly	possibly	B-ADVP	RB	O	15	PMOD	O
O	O	O	106	113	through	through	B-PP	IN	O	4	VMOD	O
O	O	O	114	117	the	the	B-NP	DT	O	17	NMOD	O
O	O	O	118	128	activation	activation	I-NP	NN	O	15	PMOD	O
O	O	O	129	131	of	of	B-PP	IN	O	17	NMOD	O
O	O	O	132	135	the	the	B-NP	DT	O	21	NMOD	O
T2	B-Entity	B-Entity	136	149	transcription	transcription	I-NP	NN	B-protein	21	NMOD	B-protein
T2	I-Entity	I-Entity	150	156	factor	factor	I-NP	NN	I-protein	25	NMOD	I-protein
T2	I-Entity	I-Entity	157	159	NF	NF	I-NP	NN	B-protein	25	NMOD	B-protein
T2	I-Entity	I-Entity	159	160	-	-	B-NP	HYPH	I-protein	25	NMOD	I-protein
T2	I-Entity	I-Entity	160	165	kappa	kappa	I-NP	NN	I-protein	25	NMOD	I-protein
T2	I-Entity	I-Entity	166	167	B	B	I-NP	NN	I-protein	18	PMOD	I-protein
O	O	O	167	168	.	.	O	.	O	4	P	O

O	O	O	170	181	Endothelial	Endothelial	B-NP	JJ	B-cell_type	3	NMOD	B-cell_type
O	O	O	182	186	cell	cell	I-NP	NN	I-cell_type	3	NMOD	I-cell_type
O	O	O	187	197	activation	activation	I-NP	NN	O	6	NMOD	O
O	O	O	198	201	and	and	O	CC	O	6	NMOD	O
O	O	O	202	211	leukocyte	leukocyte	B-NP	NN	O	6	NMOD	O
O	O	O	212	224	infiltration	infiltration	I-NP	NN	O	7	SUB	O
O	O	O	225	228	are	be	B-VP	VBP	O	0	ROOT	O
O	O	O	229	230	a	a	B-NP	DT	O	10	NMOD	O
O	O	O	231	241	consistent	consistent	I-NP	JJ	O	10	NMOD	O
O	O	O	242	249	feature	feature	I-NP	NN	O	7	PRD	O
O	O	O	250	252	of	of	B-PP	IN	O	10	NMOD	O
O	O	O	253	263	discordant	discordant	B-NP	JJ	O	14	NMOD	O
O	O	O	264	273	xenograft	xenograft	I-NP	NN	O	14	NMOD	O
O	O	O	274	283	rejection	rejection	I-NP	NN	O	11	PMOD	O
O	O	O	283	284	.	.	O	.	O	7	P	O

O	O	O	285	289	Here	Here	B-ADVP	RB	O	3	VMOD	O
O	O	O	290	292	we	we	B-NP	PRP	O	3	SUB	O
O	O	O	293	302	evaluated	evaluate	B-VP	VBD	O	0	ROOT	O
O	O	O	303	310	whether	whether	B-SBAR	IN	O	3	VMOD	O
O	O	O	311	321	xenogeneic	xenogeneic	B-NP	JJ	O	6	NMOD	O
O	O	O	322	327	serum	serum	I-NP	NN	O	18	SUB	O
O	O	O	327	328	,	,	O	,	O	6	P	O
O	O	O	329	331	as	as	B-PP	IN	O	6	NMOD	O
O	O	O	332	333	a	a	B-NP	DT	O	10	NMOD	O
O	O	O	334	340	source	source	I-NP	NN	O	8	PMOD	O
O	O	O	341	343	of	of	B-PP	IN	O	10	NMOD	O
O	O	O	344	356	xenoreactive	xenoreactive	B-NP	JJ	B-protein	14	NMOD	B-protein
O	O	O	357	364	natural	natural	I-NP	JJ	I-protein	14	NMOD	I-protein
O	O	O	365	375	antibodies	antibody	I-NP	NNS	I-protein	16	NMOD	I-protein
O	O	O	376	379	and	and	O	CC	O	16	NMOD	O
O	O	O	380	390	complement	complement	B-NP	NN	O	11	PMOD	O
O	O	O	390	391	,	,	O	,	O	6	P	O
O	O	O	392	399	induced	induce	B-VP	VBD	O	4	SBAR	O
O	O	O	400	411	endothelial	endothelial	B-NP	JJ	B-cell_type	21	NMOD	B-cell_type
O	O	O	412	416	cell	cell	I-NP	NN	I-cell_type	21	NMOD	I-cell_type
O	O	O	417	427	activation	activation	I-NP	NN	O	18	OBJ	O
O	O	O	428	432	with	with	B-PP	IN	O	18	VMOD	O
O	O	O	433	443	consequent	consequent	B-NP	JJ	O	25	NMOD	O
O	O	O	444	453	leukocyte	leukocyte	I-NP	NN	O	25	NMOD	O
O	O	O	454	462	adhesion	adhesion	I-NP	NN	O	22	PMOD	O
O	O	O	463	468	under	under	B-PP	IN	O	18	VMOD	O
O	O	O	469	473	flow	flow	B-NP	NN	O	28	NMOD	O
O	O	O	474	484	conditions	condition	I-NP	NNS	O	26	PMOD	O
O	O	O	484	485	.	.	O	.	O	3	P	O

O	O	O	486	493	Porcine	Porcine	B-NP	JJ	B-cell_line	4	NMOD	B-cell_line
O	O	O	494	500	aortic	aortic	I-NP	JJ	I-cell_line	4	NMOD	I-cell_line
O	O	O	501	512	endothelial	endothelial	I-NP	JJ	I-cell_line	4	NMOD	I-cell_line
O	O	O	513	518	cells	cell	I-NP	NNS	I-cell_line	8	SUB	I-cell_line
O	O	O	519	520	(	(	O	(	O	7	DEP	O
O	O	O	520	524	PAEC	PAEC	B-NP	NNS	B-cell_line	7	DEP	B-cell_line
O	O	O	524	525	)	)	O	)	O	4	NMOD	O
O	O	O	526	530	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	531	540	incubated	incubate	I-VP	VBN	O	8	VC	O
O	O	O	541	544	for	for	B-PP	IN	O	9	VMOD	O
O	O	O	545	546	1	1	B-NP	CD	O	14	NMOD	O
O	O	O	547	549	hr	hr	I-NP	NN	O	14	NMOD	O
O	O	O	550	552	30	30	B-NP	CD	O	14	NMOD	O
O	O	O	553	556	min	min	I-NP	NN	O	17	NMOD	O
O	O	O	557	559	or	or	O	CC	O	17	NMOD	O
O	O	O	560	561	5	5	B-NP	CD	O	17	NMOD	O
O	O	O	562	564	hr	hr	I-NP	NN	O	10	PMOD	O
O	O	O	565	569	with	with	B-PP	IN	O	9	VMOD	O
O	O	O	570	572	10	10	B-NP	CD	O	20	AMOD	O
O	O	O	572	573	%	%	I-NP	NN	O	23	NMOD	O
O	O	O	574	584	homologous	homologous	I-NP	JJ	O	23	NMOD	O
O	O	O	585	592	porcine	porcine	I-NP	JJ	O	23	NMOD	O
O	O	O	593	598	serum	serum	I-NP	NN	O	32	NMOD	O
O	O	O	599	600	(	(	O	(	O	26	DEP	O
O	O	O	600	607	control	control	B-NP	NN	O	26	DEP	O
O	O	O	607	608	)	)	O	)	O	23	NMOD	O
O	O	O	609	611	or	or	O	CC	O	32	NMOD	O
O	O	O	612	614	10	10	B-NP	CD	O	29	AMOD	O
O	O	O	614	615	%	%	I-NP	NN	O	32	NMOD	O
O	O	O	616	626	xenogeneic	xenogeneic	I-NP	JJ	O	32	NMOD	O
O	O	O	627	632	human	human	I-NP	JJ	O	32	NMOD	O
O	O	O	633	638	serum	serum	I-NP	NN	O	18	PMOD	O
O	O	O	639	642	and	and	O	CC	O	9	VMOD	O
O	O	O	643	647	then	then	B-VP	RB	O	9	VMOD	O
O	O	O	648	656	perfused	perfuse	I-VP	VBN	O	9	VMOD	O
O	O	O	657	661	with	with	B-PP	IN	O	35	VMOD	O
O	O	O	662	667	total	total	B-NP	JJ	O	39	NMOD	O
O	O	O	668	673	human	human	I-NP	JJ	B-cell_type	39	NMOD	B-cell_type
O	O	O	674	684	leukocytes	leukocyte	I-NP	NNS	I-cell_type	36	PMOD	I-cell_type
O	O	O	685	687	in	in	B-PP	IN	O	35	VMOD	O
O	O	O	688	689	a	a	B-NP	DT	O	45	NMOD	O
O	O	O	690	698	parallel	parallel	I-NP	JJ	O	45	NMOD	O
O	O	O	699	704	plate	plate	I-NP	NN	O	45	NMOD	O
O	O	O	705	709	flow	flow	I-NP	NN	O	45	NMOD	O
O	O	O	710	717	chamber	chamber	I-NP	NN	O	40	PMOD	O
O	O	O	718	723	under	under	B-PP	IN	O	35	VMOD	O
O	O	O	724	731	laminar	laminar	B-NP	JJ	O	48	NMOD	O
O	O	O	732	736	flow	flow	I-NP	NN	O	46	PMOD	O
O	O	O	737	738	(	(	O	(	O	56	DEP	O
O	O	O	738	739	1	1	B-NP	CD	O	56	DEP	O
O	O	O	739	740	.	.	O	.	O	56	P	O
O	O	O	740	741	5	5	B-NP	CD	O	55	NMOD	O
O	O	O	742	747	dynes	dyne	I-NP	NNS	O	55	NMOD	O
O	O	O	747	748	/	/	B-NP	SYM	O	55	P	O
O	O	O	748	751	cm2	cm2	I-NP	NN	O	56	DEP	O
O	O	O	751	752	)	)	O	)	O	48	NMOD	O
O	O	O	752	753	.	.	O	.	O	8	P	O

O	O	O	754	762	Adherent	Adherent	B-NP	JJ	B-cell_type	2	NMOD	B-cell_type
O	O	O	763	768	cells	cell	I-NP	NNS	I-cell_type	3	SUB	I-cell_type
O	O	O	769	773	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	774	781	counted	count	I-VP	VBN	O	3	VC	O
O	O	O	782	784	by	by	B-PP	IN	O	4	VMOD	O
O	O	O	785	792	digital	digital	B-NP	JJ	O	8	NMOD	O
O	O	O	793	798	image	image	I-NP	NN	O	8	NMOD	O
O	O	O	799	807	analysis	analysis	I-NP	NN	O	5	PMOD	O
O	O	O	807	808	.	.	O	.	O	3	P	O

O	O	O	809	819	Xenogeneic	Xenogeneic	B-NP	JJ	O	3	NMOD	O
O	O	O	820	825	human	human	I-NP	JJ	O	3	NMOD	O
O	O	O	826	831	serum	serum	I-NP	NN	O	12	SUB	O
O	O	O	832	845	significantly	significantly	B-ADVP	RB	O	12	VMOD	O
O	O	O	846	847	(	(	O	(	O	11	DEP	O
O	O	O	847	848	P	P	B-NP	NN	O	11	DEP	O
O	O	O	849	850	<	<	B-ADJP	SYM	O	6	NMOD	O
O	O	O	851	852	0	0	B-NP	CD	O	7	AMOD	O
O	O	O	852	853	.	.	I-NP	.	O	6	P	O
O	O	O	853	855	01	01	I-NP	CD	O	6	NMOD	O
O	O	O	855	856	)	)	O	)	O	4	AMOD	O
O	O	O	857	866	increased	increase	B-VP	VBD	O	0	ROOT	O
O	O	O	867	870	the	the	B-NP	DT	O	14	NMOD	O
O	O	O	871	877	number	number	I-NP	NN	O	12	OBJ	O
O	O	O	878	880	of	of	B-PP	IN	O	14	NMOD	O
O	O	O	881	889	adherent	adherent	B-NP	JJ	B-cell_type	17	NMOD	B-cell_type
O	O	O	890	900	leukocytes	leukocyte	I-NP	NNS	I-cell_type	15	PMOD	I-cell_type
O	O	O	901	903	as	as	B-PP	IN	O	12	VMOD	O
O	O	O	904	912	compared	compare	B-PP	VBN	O	18	SBAR	O
O	O	O	913	917	with	with	B-PP	IN	O	19	VMOD	O
O	O	O	918	925	porcine	porcine	B-NP	JJ	O	22	NMOD	O
O	O	O	926	931	serum	serum	I-NP	NN	O	20	PMOD	O
O	O	O	931	932	.	.	O	.	O	12	P	O

O	O	O	933	934	A	A	B-NP	DT	O	4	NMOD	O
O	O	O	935	942	similar	similar	I-NP	JJ	O	4	NMOD	O
O	O	O	943	951	adhesive	adhesive	I-NP	JJ	O	4	NMOD	O
O	O	O	952	960	response	response	I-NP	NN	O	5	SUB	O
O	O	O	961	964	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	965	973	elicited	elicit	I-VP	VBN	O	5	VC	O
O	O	O	974	976	by	by	B-PP	IN	O	6	VMOD	O
O	O	O	977	980	TNF	TNF	B-NP	NN	B-protein	9	NMOD	B-protein
O	O	O	981	986	alpha	alpha	I-NP	NN	I-protein	17	NMOD	I-protein
O	O	O	987	988	(	(	O	(	O	15	DEP	O
O	O	O	988	991	100	100	B-NP	CD	O	14	NMOD	O
O	O	O	992	993	U	U	I-NP	NN	O	14	NMOD	O
O	O	O	993	994	/	/	B-NP	SYM	O	14	NMOD	O
O	O	O	994	996	ml	ml	I-NP	NN	O	15	DEP	O
O	O	O	996	997	)	)	O	)	O	9	NMOD	O
O	O	O	997	998	,	,	O	,	O	17	P	O
O	O	O	999	1002	one	one	B-NP	CD	O	7	PMOD	O
O	O	O	1003	1005	of	of	B-PP	IN	O	17	NMOD	O
O	O	O	1006	1009	the	the	B-NP	DT	O	22	NMOD	O
O	O	O	1010	1014	most	most	I-NP	RBS	O	21	AMOD	O
O	O	O	1015	1021	potent	potent	I-NP	JJ	O	22	NMOD	O
O	O	O	1022	1030	inducers	inducer	I-NP	NNS	O	18	PMOD	O
O	O	O	1031	1033	of	of	B-PP	IN	O	22	NMOD	O
O	O	O	1034	1045	endothelial	endothelial	B-NP	JJ	B-cell_type	27	NMOD	B-cell_type
O	O	O	1046	1050	cell	cell	I-NP	NN	I-cell_type	27	NMOD	I-cell_type
O	O	O	1051	1059	adhesive	adhesive	I-NP	JJ	O	27	NMOD	O
O	O	O	1060	1070	properties	property	I-NP	NNS	O	23	PMOD	O
O	O	O	1070	1071	,	,	O	,	O	17	P	O
O	O	O	1072	1076	here	here	B-ADVP	RB	O	30	VMOD	O
O	O	O	1077	1081	used	use	B-VP	VBN	O	17	NMOD	O
O	O	O	1082	1084	as	as	B-PP	IN	O	30	VMOD	O
O	O	O	1085	1093	positive	positive	B-NP	JJ	O	33	NMOD	O
O	O	O	1094	1101	control	control	I-NP	NN	O	31	PMOD	O
O	O	O	1101	1102	.	.	O	.	O	5	P	O

O	O	O	1103	1105	In	In	B-SBAR	IN	O	16	VMOD	O
O	O	O	1106	1111	order	order	O	NN	O	1	DEP	O
O	O	O	1112	1114	to	to	B-VP	TO	O	4	VMOD	O
O	O	O	1115	1124	elucidate	elucidate	I-VP	VB	O	1	SBAR	O
O	O	O	1125	1133	possible	possible	B-NP	JJ	O	6	NMOD	O
O	O	O	1134	1144	mechanisms	mechanism	I-NP	NNS	O	4	OBJ	O
O	O	O	1145	1155	underlying	underlie	B-VP	VBG	O	6	NMOD	O
O	O	O	1156	1167	endothelial	endothelial	B-NP	JJ	B-cell_type	9	NMOD	B-cell_type
O	O	O	1168	1172	cell	cell	I-NP	NN	I-cell_type	10	NMOD	I-cell_type
O	O	O	1173	1183	activation	activation	I-NP	NN	O	7	OBJ	O
O	O	O	1184	1186	by	by	B-PP	IN	O	10	NMOD	O
O	O	O	1187	1197	xenogeneic	xenogeneic	B-NP	JJ	O	13	NMOD	O
O	O	O	1198	1203	serum	serum	I-NP	NN	O	11	PMOD	O
O	O	O	1203	1204	,	,	O	,	O	16	P	O
O	O	O	1205	1207	we	we	B-NP	PRP	O	16	SUB	O
O	O	O	1208	1216	focussed	focusse	B-VP	VBD	O	0	ROOT	O
O	O	O	1217	1219	on	on	B-PP	IN	O	16	VMOD	O
T3	B-Entity	B-Entity	1220	1233	transcription	transcription	B-NP	NN	B-protein	19	NMOD	B-protein
T3	I-Entity	I-Entity	1234	1240	factor	factor	I-NP	NN	I-protein	23	NMOD	I-protein
T3	I-Entity	I-Entity	1241	1243	NF	NF	I-NP	NN	B-protein	23	NMOD	B-protein
T3	I-Entity	I-Entity	1243	1244	-	-	B-NP	HYPH	I-protein	23	NMOD	I-protein
T3	I-Entity	I-Entity	1244	1249	kappa	kappa	I-NP	NN	I-protein	23	NMOD	I-protein
T3	I-Entity	I-Entity	1250	1251	B	B	I-NP	NN	I-protein	27	NMOD	I-protein
O	O	O	1251	1252	,	,	O	,	O	27	P	O
O	O	O	1253	1254	a	a	B-NP	DT	O	27	NMOD	O
O	O	O	1255	1262	central	central	I-NP	JJ	O	27	NMOD	O
O	O	O	1263	1272	regulator	regulator	I-NP	NN	O	17	PMOD	O
O	O	O	1273	1276	for	for	B-PP	IN	O	27	NMOD	O
O	O	O	1277	1280	the	the	B-NP	DT	O	30	NMOD	O
O	O	O	1281	1290	induction	induction	I-NP	NN	O	28	PMOD	O
O	O	O	1291	1293	of	of	B-PP	IN	O	30	NMOD	O
O	O	O	1294	1303	different	different	B-NP	JJ	O	33	NMOD	O
O	O	O	1304	1309	genes	gene	I-NP	NNS	O	31	PMOD	O
O	O	O	1309	1310	,	,	O	,	O	33	P	O
O	O	O	1311	1320	including	include	B-PP	VBG	O	33	NMOD	O
O	O	O	1321	1329	adhesive	adhesive	B-NP	JJ	B-protein	37	NMOD	B-protein
O	O	O	1330	1339	molecules	molecule	I-NP	NNS	I-protein	39	NMOD	I-protein
O	O	O	1340	1343	and	and	I-NP	CC	O	39	NMOD	O
O	O	O	1344	1360	chemoattractants	chemoattractant	I-NP	NNS	B-protein	35	PMOD	B-protein
O	O	O	1360	1361	.	.	O	.	O	16	P	O

O	O	O	1362	1364	By	By	B-PP	IN	O	7	VMOD	O
O	O	O	1365	1373	confocal	confocal	B-NP	JJ	O	4	NMOD	O
O	O	O	1374	1386	fluorescence	fluorescence	I-NP	NN	O	4	NMOD	O
O	O	O	1387	1397	microscopy	microscopy	I-NP	NN	O	1	PMOD	O
O	O	O	1397	1398	,	,	O	,	O	7	P	O
O	O	O	1399	1401	we	we	B-NP	PRP	O	7	SUB	O
O	O	O	1402	1410	observed	observe	B-VP	VBD	O	0	ROOT	O
O	O	O	1411	1412	a	a	B-NP	DT	O	10	NMOD	O
O	O	O	1413	1421	positive	positive	I-NP	JJ	O	10	NMOD	O
O	O	O	1422	1430	staining	staining	I-NP	NN	O	7	OBJ	O
O	O	O	1431	1434	for	for	B-PP	IN	O	10	NMOD	O
O	O	O	1435	1437	NF	NF	B-NP	NN	B-protein	15	NMOD	B-protein
O	O	O	1437	1438	-	-	O	HYPH	I-protein	15	NMOD	I-protein
O	O	O	1438	1443	kappa	kappa	B-NP	NN	I-protein	15	NMOD	I-protein
O	O	O	1444	1445	B	B	I-NP	NN	I-protein	11	PMOD	I-protein
O	O	O	1446	1447	(	(	O	(	O	19	DEP	O
T1	B-Protein	B-Protein	1447	1450	p65	p65	B-NP	NN	B-protein	18	NMOD	B-protein
O	O	O	1451	1458	subunit	subunit	I-NP	NN	I-protein	19	DEP	I-protein
O	O	O	1458	1459	)	)	O	)	O	15	NMOD	O
O	O	O	1460	1462	in	in	B-PP	IN	O	10	NMOD	O
O	O	O	1463	1466	the	the	B-NP	DT	O	22	NMOD	O
O	O	O	1467	1473	nuclei	nucleus	I-NP	NNS	O	20	PMOD	O
O	O	O	1474	1476	of	of	B-PP	IN	O	22	NMOD	O
O	O	O	1477	1481	PAEC	PAEC	B-NP	NNS	B-cell_line	23	PMOD	B-cell_line
O	O	O	1482	1489	exposed	expose	B-VP	VBN	O	24	NMOD	O
O	O	O	1490	1493	for	for	B-PP	IN	O	25	VMOD	O
O	O	O	1494	1495	1	1	B-NP	CD	O	30	NMOD	O
O	O	O	1496	1498	hr	hr	I-NP	NN	O	30	NMOD	O
O	O	O	1499	1501	30	30	B-NP	CD	O	30	NMOD	O
O	O	O	1502	1505	min	min	I-NP	NN	O	26	PMOD	O
O	O	O	1506	1508	to	to	B-PP	TO	O	30	NMOD	O
O	O	O	1509	1514	human	human	B-NP	JJ	O	33	NMOD	O
O	O	O	1515	1520	serum	serum	I-NP	NN	O	31	PMOD	O
O	O	O	1520	1521	,	,	O	,	O	10	P	O
O	O	O	1522	1527	which	which	B-NP	WDT	O	10	NMOD	O
O	O	O	1528	1537	indicated	indicate	B-VP	VBD	O	35	SBAR	O
T4	B-Entity	B-Entity	1538	1540	NF	NF	B-NP	NN	B-protein	41	NMOD	B-protein
T4	I-Entity	I-Entity	1540	1541	-	-	B-NP	HYPH	I-protein	41	NMOD	I-protein
T4	I-Entity	I-Entity	1541	1546	kappa	kappa	I-NP	NN	I-protein	41	NMOD	I-protein
T4	I-Entity	I-Entity	1547	1548	B	B	I-NP	NN	I-protein	41	NMOD	I-protein
O	O	O	1549	1559	activation	activation	I-NP	NN	O	36	OBJ	O
O	O	O	1560	1562	in	in	B-PP	IN	O	41	NMOD	O
O	O	O	1563	1567	this	this	B-NP	DT	O	44	NMOD	O
O	O	O	1568	1575	setting	setting	I-NP	NN	O	42	PMOD	O
O	O	O	1575	1576	.	.	O	.	O	7	P	O

O	O	O	1577	1579	At	At	B-PP	IN	O	16	VMOD	O
O	O	O	1580	1588	variance	variance	B-NP	NN	O	1	PMOD	O
O	O	O	1588	1589	,	,	O	,	O	16	P	O
O	O	O	1590	1592	in	in	B-PP	IN	O	16	VMOD	O
O	O	O	1593	1597	PAEC	PAEC	B-NP	NNS	B-cell_line	4	PMOD	B-cell_line
O	O	O	1598	1607	incubated	incubate	B-VP	VBN	O	5	NMOD	O
O	O	O	1608	1612	with	with	B-PP	IN	O	6	VMOD	O
O	O	O	1613	1616	the	the	B-NP	DT	O	10	NMOD	O
O	O	O	1617	1627	homologous	homologous	I-NP	JJ	O	10	NMOD	O
O	O	O	1628	1633	serum	serum	I-NP	NN	O	7	PMOD	O
O	O	O	1633	1634	,	,	O	,	O	16	P	O
T5	B-Entity	B-Entity	1635	1637	NF	NF	B-NP	NN	B-protein	15	NMOD	B-protein
T5	I-Entity	I-Entity	1637	1638	-	-	B-NP	HYPH	I-protein	15	NMOD	I-protein
T5	I-Entity	I-Entity	1638	1643	kappa	kappa	I-NP	NN	I-protein	15	NMOD	I-protein
T5	I-Entity	I-Entity	1644	1645	B	B	I-NP	NN	I-protein	16	SUB	I-protein
O	O	O	1646	1649	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1650	1658	strictly	strictly	I-VP	RB	O	16	VMOD	O
O	O	O	1659	1668	localized	localize	I-VP	VBN	O	16	VC	O
O	O	O	1669	1671	in	in	B-PP	IN	O	18	VMOD	O
O	O	O	1672	1675	the	the	B-NP	DT	O	22	NMOD	O
O	O	O	1676	1680	cell	cell	I-NP	NN	O	22	NMOD	O
O	O	O	1681	1690	cytoplasm	cytoplasm	I-NP	NN	O	19	PMOD	O
O	O	O	1690	1691	.	.	O	.	O	16	P	O

O	O	O	1692	1701	Treatment	Treatment	B-NP	NN	O	0	ROOT	O
O	O	O	1702	1704	of	of	B-PP	IN	O	1	NMOD	O
O	O	O	1705	1709	PAEC	PAEC	B-NP	NNS	B-cell_line	2	PMOD	B-cell_line
O	O	O	1710	1717	exposed	expose	B-VP	VBN	O	3	NMOD	O
O	O	O	1718	1720	to	to	B-PP	TO	O	4	VMOD	O
O	O	O	1721	1731	xenogeneic	xenogeneic	B-NP	JJ	O	7	NMOD	O
O	O	O	1732	1737	serum	serum	I-NP	NN	O	5	PMOD	O
O	O	O	1738	1742	with	with	B-PP	IN	O	1	NMOD	O
O	O	O	1743	1746	the	the	B-NP	DT	O	14	NMOD	O
T6	B-Entity	B-Entity	1747	1749	NF	NF	I-NP	NN	B-protein	14	NMOD	B-protein
T6	I-Entity	I-Entity	1749	1750	-	-	B-NP	HYPH	I-protein	14	NMOD	I-protein
T6	I-Entity	I-Entity	1750	1755	kappa	kappa	I-NP	NN	I-protein	14	NMOD	I-protein
T6	I-Entity	I-Entity	1756	1757	B	B	I-NP	NN	I-protein	14	NMOD	I-protein
O	O	O	1758	1768	inhibitors	inhibitor	I-NP	NNS	O	40	SUB	O
O	O	O	1769	1795	pyrrolidinedithiocarbamate	pyrrolidinedithiocarbamate	B-NP	NN	O	40	SUB	O
O	O	O	1796	1797	(	(	O	(	O	21	DEP	O
O	O	O	1797	1801	PDTC	PDTC	B-NP	NN	O	20	NMOD	O
O	O	O	1801	1802	,	,	O	,	O	20	P	O
O	O	O	1803	1805	25	25	B-NP	CD	O	20	NMOD	O
O	O	O	1806	1812	microM	microM	I-NP	NN	O	21	DEP	O
O	O	O	1812	1813	)	)	O	)	O	15	NMOD	O
O	O	O	1814	1817	and	and	O	CC	O	40	VMOD	O
O	O	O	1818	1823	tosyl	tosyl	B-NP	NN	O	40	SUB	O
O	O	O	1823	1824	-	-	O	HYPH	O	40	P	O
O	O	O	1824	1845	phechloromethylketone	phechloromethylketone	B-NP	NN	O	40	SUB	O
O	O	O	1846	1847	(	(	O	(	O	31	DEP	O
O	O	O	1847	1851	TPCK	TPCK	B-NP	NN	O	30	NMOD	O
O	O	O	1851	1852	,	,	O	,	O	30	P	O
O	O	O	1853	1855	25	25	B-NP	CD	O	30	NMOD	O
O	O	O	1856	1862	microM	microM	I-NP	NN	O	31	DEP	O
O	O	O	1862	1863	)	)	O	)	O	25	NMOD	O
O	O	O	1864	1877	significantly	significantly	B-ADVP	RB	O	40	VMOD	O
O	O	O	1878	1879	(	(	O	(	O	39	DEP	O
O	O	O	1879	1880	P	P	B-NP	NN	O	39	DEP	O
O	O	O	1881	1882	<	<	B-ADJP	SYM	O	34	NMOD	O
O	O	O	1883	1884	0	0	B-NP	CD	O	35	AMOD	O
O	O	O	1884	1885	.	.	I-NP	.	O	34	P	O
O	O	O	1885	1887	01	01	I-NP	CD	O	34	NMOD	O
O	O	O	1887	1888	)	)	O	)	O	32	AMOD	O
O	O	O	1889	1896	reduced	reduce	B-VP	VBD	O	8	SBAR	O
O	O	O	1897	1906	leukocyte	leukocyte	B-NP	NN	O	42	NMOD	O
O	O	O	1907	1915	adhesion	adhesion	I-NP	NN	O	40	OBJ	O
O	O	O	1916	1918	in	in	B-PP	IN	O	40	VMOD	O
O	O	O	1919	1926	respect	respect	B-NP	NN	O	43	PMOD	O
O	O	O	1927	1929	to	to	B-PP	TO	O	44	NMOD	O
O	O	O	1930	1934	PAEC	PAEC	B-NP	NNS	B-cell_line	45	PMOD	B-cell_line
O	O	O	1935	1942	treated	treat	B-VP	VBN	O	46	NMOD	O
O	O	O	1943	1947	with	with	B-PP	IN	O	47	VMOD	O
O	O	O	1948	1953	human	human	B-NP	JJ	O	50	NMOD	O
O	O	O	1954	1959	serum	serum	I-NP	NN	O	48	PMOD	O
O	O	O	1960	1965	alone	alone	B-ADVP	RB	O	50	NMOD	O
O	O	O	1965	1966	.	.	O	.	O	1	P	O

O	O	O	1967	1975	Findings	Finding	B-NP	NNS	O	0	ROOT	O
O	O	O	1976	1980	that	that	B-SBAR	IN	O	1	NMOD	O
O	O	O	1981	1991	xenogeneic	xenogeneic	B-NP	JJ	O	4	NMOD	O
O	O	O	1992	1997	serum	serum	I-NP	NN	O	5	SUB	O
O	O	O	1998	2006	promotes	promote	B-VP	VBZ	O	2	SBAR	O
O	O	O	2007	2016	leukocyte	leukocyte	B-NP	NN	B-cell_type	9	NMOD	B-cell_type
O	O	O	2016	2017	-	-	I-NP	HYPH	O	9	P	O
O	O	O	2017	2028	endothelium	endothelium	I-NP	NN	O	9	NMOD	O
O	O	O	2029	2040	interaction	interaction	I-NP	NN	O	5	OBJ	O
O	O	O	2041	2049	possibly	possibly	B-ADVP	RB	O	11	PMOD	O
O	O	O	2050	2057	through	through	B-PP	IN	O	5	VMOD	O
T7	B-Entity	B-Entity	2058	2060	NF	NF	B-NP	NN	B-protein	15	NMOD	B-protein
T7	I-Entity	I-Entity	2060	2061	-	-	B-NP	HYPH	I-protein	15	NMOD	I-protein
T7	I-Entity	I-Entity	2061	2066	kappa	kappa	I-NP	NN	I-protein	15	NMOD	I-protein
T7	I-Entity	I-Entity	2067	2068	B	B	I-NP	NN	I-protein	16	NMOD	I-protein
O	O	O	2069	2079	activation	activation	I-NP	NN	O	11	PMOD	O
O	O	O	2080	2085	might	might	B-VP	MD	O	11	SBAR	O
O	O	O	2086	2088	be	be	I-VP	VB	O	17	VC	O
O	O	O	2089	2097	relevant	relevant	B-ADJP	JJ	O	18	PRD	O
O	O	O	2098	2101	for	for	B-PP	IN	O	19	AMOD	O
O	O	O	2102	2111	designing	design	B-VP	VBG	O	20	PMOD	O
O	O	O	2112	2118	future	future	B-NP	JJ	O	23	AMOD	O
O	O	O	2119	2130	therapeutic	therapeutic	I-NP	JJ	O	24	NMOD	O
O	O	O	2131	2141	strategies	strategy	I-NP	NNS	O	21	OBJ	O
O	O	O	2142	2147	aimed	aim	B-VP	VBN	O	24	NMOD	O
O	O	O	2148	2150	at	at	B-PP	IN	O	25	VMOD	O
O	O	O	2151	2161	prolonging	prolong	B-VP	VBG	O	26	PMOD	O
O	O	O	2162	2171	xenograft	xenograft	B-NP	NN	O	29	NMOD	O
O	O	O	2172	2180	survival	survival	I-NP	NN	O	27	OBJ	O
O	O	O	2180	2181	.	.	O	.	O	1	P	O
